Nuvectis Pharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ron Bentsur
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Bridge Plaza Fort Lee NJ United States of America 07024
- IPO Date
- Feb 4, 2022
- CIK
- 0001875558
- Website
- nuvectis.com
- Similar Companies
- Business
- Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharmaceutical company that develops precision medicines for serious unmet needs in oncology. The company focuses on novel small-molecule drug candidates, including its lead asset NXP900, an oral inhibitor of SRC family kinases (SFK) targeting proto-oncogenes c-Src and YES1 to block both catalytic and scaffolding functions in signaling pathways for solid tumors; and NXP800, a GCN2 kinase activator that induces integrated stress response and cap-dependent protein translation inhibition for ARID1a-mutated cancers. NXP900 advances in Phase 1b trials as monotherapy for YES1/SRC-driven solid tumors and in combination for ALK-positive/EGFR-mutated NSCLC, following successful completion of Phase 1a dose escalation and drug-drug interaction studies showing favorable safety with mild gastrointestinal effects and over 90% kinase inhibition at higher doses; NXP800 progresses in Phase 1b for platinum-resistant ARID1a-mutated ovarian cancer with Fast Track and Orphan Drug Designations, plus an investigator-sponsored trial in cholangiocarcinoma with Orphan Drug Designation. Founded in 2020 and headquartered in Fort Lee, New Jersey, the company, formerly Centry Pharma, Inc., operates primarily in the United States with a global development focus on oncology patient populations. Recent developments include discontinuation of NXP800 expansion in ovarian cancer after mixed Phase 1b data showing 33% response rate and 100% disease control in evaluable patients, with reprioritization toward NXP900 as the lead candidate and exploration of NXP800 in endometrial and prostate cancers; strengthening of cash position to $39 million pro forma as of June 2025 via at-the-market equity sales to a healthcare investor, funding operations into late 2027; poster presentations at the 2025 AACR-NCI-EORTC conference supporting NXP900's biomarker strategy; and Q3 2025 financials reflecting $7.5 million net loss amid pipeline investment.
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy?
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
Nuvectis (NVCT) Q2 Loss Widens 43%
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights